v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Integer
shares
Jun. 30, 2025
USD ($)
shares
Dec. 31, 2025
Product Information [Line Items]          
Research and development expense | $ $ 332 $ 910 $ 707 $ 1,690  
Antidilutive securities excluded from computation of earnings per share, amount | shares     36,735,129 26,560,392  
Number of operating segment     1    
Number of reportable segment     1    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customers [Member]          
Product Information [Line Items]          
Concentration risk, percentage     0.00%    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]          
Product Information [Line Items]          
Concentration risk, percentage         16.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customers [Member]          
Product Information [Line Items]          
Concentration risk, percentage     15.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]          
Product Information [Line Items]          
Concentration risk, percentage       66.00%